IT1250064B - Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali. - Google Patents

Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali.

Info

Publication number
IT1250064B
IT1250064B ITRM910788A ITRM910788A IT1250064B IT 1250064 B IT1250064 B IT 1250064B IT RM910788 A ITRM910788 A IT RM910788A IT RM910788 A ITRM910788 A IT RM910788A IT 1250064 B IT1250064 B IT 1250064B
Authority
IT
Italy
Prior art keywords
preparation
reducing conditions
purification
procedure
medicinal products
Prior art date
Application number
ITRM910788A
Other languages
English (en)
Italian (it)
Inventor
Paul Ian Nicholas Ramage
Geoffrey Allen
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1250064(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ITRM910788A0 publication Critical patent/ITRM910788A0/it
Publication of ITRM910788A1 publication Critical patent/ITRM910788A1/it
Application granted granted Critical
Publication of IT1250064B publication Critical patent/IT1250064B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ITRM910788A 1990-10-17 1991-10-16 Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali. IT1250064B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin

Publications (3)

Publication Number Publication Date
ITRM910788A0 ITRM910788A0 (it) 1991-10-16
ITRM910788A1 ITRM910788A1 (it) 1993-04-16
IT1250064B true IT1250064B (it) 1995-03-30

Family

ID=10683866

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM910788A IT1250064B (it) 1990-10-17 1991-10-16 Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali.

Country Status (29)

Country Link
US (1) US5644036A (cg-RX-API-DMAC7.html)
EP (1) EP0504363B2 (cg-RX-API-DMAC7.html)
JP (1) JP2638680B2 (cg-RX-API-DMAC7.html)
KR (2) KR960015399B1 (cg-RX-API-DMAC7.html)
AT (2) ATE162552T1 (cg-RX-API-DMAC7.html)
AU (3) AU658926B2 (cg-RX-API-DMAC7.html)
BE (1) BE1004226A5 (cg-RX-API-DMAC7.html)
BR (1) BR1100358A (cg-RX-API-DMAC7.html)
CA (1) CA2069481C (cg-RX-API-DMAC7.html)
CH (2) CH681455A5 (cg-RX-API-DMAC7.html)
DE (1) DE69128774T3 (cg-RX-API-DMAC7.html)
DK (1) DK0504363T4 (cg-RX-API-DMAC7.html)
ES (2) ES2112865T5 (cg-RX-API-DMAC7.html)
FI (2) FI110003B (cg-RX-API-DMAC7.html)
FR (2) FR2668164A1 (cg-RX-API-DMAC7.html)
GB (2) GB9022547D0 (cg-RX-API-DMAC7.html)
GR (3) GR910100425A (cg-RX-API-DMAC7.html)
HU (1) HUT64601A (cg-RX-API-DMAC7.html)
IE (1) IE913560A1 (cg-RX-API-DMAC7.html)
IL (3) IL102726A (cg-RX-API-DMAC7.html)
IT (1) IT1250064B (cg-RX-API-DMAC7.html)
LU (1) LU88122A1 (cg-RX-API-DMAC7.html)
MX (1) MX9203794A (cg-RX-API-DMAC7.html)
MY (2) MY119030A (cg-RX-API-DMAC7.html)
NZ (2) NZ244114A (cg-RX-API-DMAC7.html)
PT (2) PT99248B (cg-RX-API-DMAC7.html)
TW (1) TW283710B (cg-RX-API-DMAC7.html)
WO (1) WO1992007084A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA918259B (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
IL103418A (en) * 1991-10-15 1997-11-20 Wellcome Found Therapeutic agent for the t-cell mediated inflammation of the joints and its production
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
NZ315357A (en) † 1995-08-01 1999-08-30 Pasteur Merieux Serums Vacc Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP2336149A1 (en) 2001-03-09 2011-06-22 Chugai Seiyaku Kabushiki Kaisha Protein purification method
JP4288153B2 (ja) * 2001-06-05 2009-07-01 ジェネティクス インスティテュート，エルエルシー 非常に陰イオン性であるタンパク質を精製する方法
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
EP1561756B1 (en) 2002-09-11 2015-12-23 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
EP2314604A3 (en) 2002-10-15 2011-05-25 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
BRPI0417993A (pt) * 2003-12-22 2007-04-27 Genzyme Corp anticorpo anti-cd52 para tratamento da diabetes
CN104610422A (zh) * 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
KR101463631B1 (ko) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
US20110111406A1 (en) 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
AU2010248935B2 (en) 2009-05-13 2016-12-15 Genzyme Corporation Methods and compositions for treating lupus
SG176060A1 (en) 2009-05-13 2011-12-29 Genzyme Corp Anti-human cd52 immunoglobulins
WO2011090719A2 (en) * 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd. Protein purification by ion exchange
US20130096284A1 (en) 2010-06-21 2013-04-18 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112016014824A2 (pt) 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
EP3330279B1 (en) 2015-07-31 2022-04-06 Chugai Seiyaku Kabushiki Kaisha Method for purifying composition comprising antibodies with anionic polymer
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CA3031028C (en) 2016-07-25 2024-02-13 Lu Wang Affinity chromatography wash buffer
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
US20220177518A1 (en) 2019-03-29 2022-06-09 Asahi Kasei Medical Co., Ltd. Method for purifying protein
EP3954725B1 (en) 2019-04-08 2024-03-06 Asahi Kasei Medical Co., Ltd. Polyamide medium for purifying protein-containing solution and method for producing polyamide medium
TW202104244A (zh) 2019-04-10 2021-02-01 日商中外製藥股份有限公司 Fc區域改變抗體的純化方法
JPWO2022260091A1 (cg-RX-API-DMAC7.html) 2021-06-10 2022-12-15

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.

Also Published As

Publication number Publication date
FR2668164B1 (cg-RX-API-DMAC7.html) 1995-04-14
GB9022547D0 (en) 1990-11-28
FI110002B (fi) 2002-11-15
ITRM910788A0 (it) 1991-10-16
ITRM910788A1 (it) 1993-04-16
KR960015399B1 (ko) 1996-11-13
KR100193314B1 (ko) 1999-06-15
NZ240247A (en) 1994-03-25
ES2081742A1 (es) 1996-03-01
MX9203794A (es) 1992-07-01
PT99248B (pt) 1999-04-30
CA2069481A1 (en) 1992-04-18
DE69128774T3 (de) 2007-08-16
FI922380L (fi) 1992-05-25
ZA918259B (en) 1993-04-16
DE69128774D1 (de) 1998-02-26
GB2253397A (en) 1992-09-09
BR1100358A (pt) 2000-03-28
TW283710B (cg-RX-API-DMAC7.html) 1996-08-21
MY119030A (en) 2005-03-31
KR920703108A (ko) 1992-12-17
GR920100471A (el) 1994-06-30
AU716402B2 (en) 2000-02-24
EP0504363A1 (en) 1992-09-23
EP0504363B1 (en) 1998-01-21
FI110003B (fi) 2002-11-15
GR910100425A (el) 1992-09-25
FI922380A0 (fi) 1992-05-25
HU9202000D0 (en) 1992-10-28
AU7024294A (en) 1995-01-05
ZA926191B (en) 1993-04-16
ES2112865T3 (es) 1998-04-16
NZ244114A (en) 1995-06-27
AU8729491A (en) 1992-05-20
EP0504363B2 (en) 2007-02-07
LU88122A1 (fr) 1993-03-15
FI922824A0 (fi) 1992-06-17
CH681455A5 (cg-RX-API-DMAC7.html) 1993-03-31
JPH05504579A (ja) 1993-07-15
BE1004226A5 (fr) 1992-10-13
IL102726A (en) 2002-08-14
ES2081742B1 (es) 1996-10-01
DK0504363T3 (da) 1998-09-21
MY136210A (en) 2008-08-29
DK0504363T4 (da) 2007-05-29
CA2069481C (en) 2003-07-29
AU649078B2 (en) 1994-05-12
IE913560A1 (en) 1992-04-22
AU4521897A (en) 1998-02-12
PT100988B (pt) 1999-08-31
US5644036A (en) 1997-07-01
ATE162552T1 (de) 1998-02-15
AU2532192A (en) 1993-02-11
PT100988A (pt) 1994-02-28
FI922824L (fi) 1992-06-17
JP2638680B2 (ja) 1997-08-06
ATA900791A (de) 1996-06-15
GB9209529D0 (en) 1992-07-01
HUT64601A (en) 1994-01-28
FR2677997A1 (fr) 1992-12-24
AU658926B2 (en) 1995-05-04
WO1992007084A1 (en) 1992-04-30
PT99248A (pt) 1993-06-30
ES2112865T5 (es) 2007-09-16
GR3026588T3 (en) 1998-07-31
IL102726A0 (en) 1993-01-31
DE69128774T2 (de) 1998-06-04
IL99761A0 (en) 1992-08-18
CH681305A5 (cg-RX-API-DMAC7.html) 1993-02-26
FR2668164A1 (fr) 1992-04-24

Similar Documents

Publication Publication Date Title
IT1250064B (it) Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali.
AR216774A1 (es) Procedimiento para preparar una composicion cosmeticamente aceptable para aplicacion topica a la piel humana
AR229725A1 (es) Composicion acuosa cosmeticamente aceptable para aplicacion topica a la piel humana
IT7967023A0 (it) Derivati di prostaciclina e procedimento per la loro preparazione
BR1100860A (pt) Composto, droga antiinflamatória, composição farmacêutica, epìmero r e epìmero s do composto
IT8349185A0 (it) Derivati eterociclici dell'etanolo, loro preparazione e loro impiego come fungicidi
ES2143978T3 (es) Utilizacion de esteroides para la inhibicion de la angiogenesis.
AU554345B2 (en) Tricyclic antidepressant drug immunogens, antibodies labelled conjugates, and related derivatives
ES537330A0 (es) Un procedimiento para producir un peptido que comprende un peptido de exo-senal unido operativamente a una proteina deseada
EP0005476A3 (en) Process for preparing human interferon, human interferons prepared by this process and their therapeutical applications
IT8009551A0 (it) E-5-(2-alogenovinil-)-2'deossicitidine, loro metodo di preparazione e loro impiego per il trattamentodi malattie da virus
ES489521A0 (es) Un procedimiento para la preparacion de un peptido
DK0700897T3 (da) L-carnitinsalt og kosmetiske og farmaceutiske præparater indeholdende samme til behandling af hudsygdomme
IT1200944B (it) Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
AU617036B2 (en) Phenylhydrazones, the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom
YU2292A (sh) Antibakterijska sredstva
IT1114721B (it) Derivati di 3,3-dicloro-2-azetidinone ad attivita' anti-infiammatoria
PH18734A (en) Panthenol derivatives and their pharmaceutical composition
AU685022B2 (en) Native type II GAP, methods for purifying various GAPs and uses of GAPs to diagnose cancer
FR2751324B1 (fr) Synthese du 1,1,1-trifluoroethane par fluoration du 1-chloro-1,1,-difluoroethane
IT1233005B (it) Anticorpo umano monoclonale, composizione terapeutica che lo contiene linea cellulare capace di produrre l'anticorpo, procedimento per la sua produzione
IT1096576B (it) Prodotto cosmetico antisolare per il campo uv - a.
FI934468A7 (fi) Bentseeniboorihappojohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö synteesin välituotteina
IT8349163A0 (it) 5h-dibenz/b,f/azepin-5-carbossamidi loro prodotti intermedi, preparati farmaceutici che le contengono, procedimento per produrle e loro impiego
ITMI932555A0 (it) Procedimento per la regolazione dello stiro di un prodotto da laminare

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19951027